Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer

Cancers

Maria Silvia Cona¹  Antonino Belfiore²  Giancarlo Pruneri²  Claudio Vernieri³  Sara Manglaviti⁴  Giuseppe Capri⁴  Michele Prisciandaro⁴  Giorgia Peverelli⁴  Federico Nichetti⁴  Francesca Corti⁴  Filippo de Braud⁴  Riccardo Lobefaro⁴  Gabriella Mariani⁴  Giulia Valeria Bianchi⁴  Luigi Celio⁴  Marta Brambilla⁴  Francesca Ligorio⁴  Pierangela Sepe⁴  Emma Zattarin⁴  Barbara Re⁵  Licia Rivoltini⁶ 

[1] ASST Fatebenefratelli Sacco – PO Luigi Sacco, Milan, Italy, Via G.B. Grassi 74, 20133 Milan, Italy;Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy;Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Via Adamello 16, 20133 Milan, Italy;Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy;SC Pharmacy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy;Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy;

关键词: advanced breast cancer;    chemotherapy;    capecitabine;    vinorelbine;    hormone receptor-positive breast cancer;    triple-negative breast cancer;    progression-free survival;    overall survival;    adverse events;   

DOI  :  10.3390/cancers12030617

来源: DOAJ

【 摘 要 】

Background: Single-agent capecitabine (C) is a moderately effective chemotherapeutic compound in the treatment of patients with HER2-negative metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is also used due to a good tolerability profile, but no studies have demonstrated its superiority over single-agent C. Methods: We conducted a retrospective analysis to compare overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and incidence of adverse events (AEs) in patients with HER2-negative mBC treated with CV vs. single-agent C. Results: Out of 290 patients included in this study, 127 (43.8%) received single-agent C, while 163 (56.2%) patients were treated with CV. Median PFS was similar in patients treated with single-agent C or CV, while CV was associated with significantly longer OS in patients with hormone receptor-positive (HR+) BC. This OS advantage was confirmed at multivariable analysis also after propensity score-based matching of patients according to relevant clinical or tumor characteristics. When compared with single-agent C, CV was associated with higher incidence of G3/G4 and any-grade nausea/vomiting, diarrhea and increased transaminases. Conclusions: While prospective studies are needed to confirm our findings, the potential OS advantage of CV over single-agent C in HR+ mBC patients must be weighed against a significantly higher incidence of AEs.

【 授权许可】

Unknown